Renate Jonker1, Nicolaas Ep Deutz2, Marcia L Erbland3, Paula J Anderson3, Mariëlle Pkj Engelen1. 1. Center for Translational Research in Aging and Longevity, Department of Health and Kinesiology, Texas A&M University, College Station, TX; and Departments of Geriatrics and. 2. Center for Translational Research in Aging and Longevity, Department of Health and Kinesiology, Texas A&M University, College Station, TX; and Departments of Geriatrics and nep.deutz@ctral.org. 3. Pulmonary and Critical Care Medicine, University of Arkansas for Medical Sciences, Little Rock, AR.
Abstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a condition characterized by systemic low-grade inflammation that could increase the production of nitric oxide (NO), of which arginine is the sole precursor. Arginine is derived from the breakdown of protein and through the conversion of citrulline to arginine (de novo arginine production). OBJECTIVE: Our objective was to study whole-body arginine and citrulline and related metabolism in stable COPD patients. DESIGN: With the use of stable isotope methodology, we studied whole-body arginine and citrulline rates of appearance, de novo arginine (citrulline-to-arginine flux) and NO (arginine-to-citrulline flux) production, protein synthesis and breakdown rates, and plasma amino acid concentrations in a heterogeneous group of patients with moderate-to-severe COPD [n = 23, mean ± SE age: 65 ± 2 y, forced expiratory volume in 1 s (FEV1): 40% ± 2% of predicted], and a group of healthy older adults (n = 19, mean ± SE age: 64 ± 2 y, FEV1: 95% ± 4% of predicted). RESULTS: Although plasma arginine and citrulline concentrations were comparable between COPD patients and controls, whole-body arginine (P = 0.015) and citrulline (P = 0.026) rates of appearance were higher in COPD patients and related to a 57% greater de novo arginine production (P < 0.0001). Despite a higher whole-body arginine clearance in COPD patients (P < 0.0001), we found no difference in NO production. CONCLUSION: In stable patients with moderate-to-severe COPD, endogenous arginine production is upregulated to support a higher arginine utilization that is unrelated to whole-body NO production. This trial was registered at clinicaltrials.gov as NCT01173354 and NCT01172314.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a condition characterized by systemic low-grade inflammation that could increase the production of nitric oxide (NO), of which arginine is the sole precursor. Arginine is derived from the breakdown of protein and through the conversion of citrulline to arginine (de novo arginine production). OBJECTIVE: Our objective was to study whole-body arginine and citrulline and related metabolism in stable COPDpatients. DESIGN: With the use of stable isotope methodology, we studied whole-body arginine and citrulline rates of appearance, de novo arginine (citrulline-to-arginine flux) and NO (arginine-to-citrulline flux) production, protein synthesis and breakdown rates, and plasma amino acid concentrations in a heterogeneous group of patients with moderate-to-severe COPD [n = 23, mean ± SE age: 65 ± 2 y, forced expiratory volume in 1 s (FEV1): 40% ± 2% of predicted], and a group of healthy older adults (n = 19, mean ± SE age: 64 ± 2 y, FEV1: 95% ± 4% of predicted). RESULTS: Although plasma arginine and citrulline concentrations were comparable between COPDpatients and controls, whole-body arginine (P = 0.015) and citrulline (P = 0.026) rates of appearance were higher in COPDpatients and related to a 57% greater de novo arginine production (P < 0.0001). Despite a higher whole-body arginine clearance in COPDpatients (P < 0.0001), we found no difference in NO production. CONCLUSION: In stable patients with moderate-to-severe COPD, endogenous arginine production is upregulated to support a higher arginine utilization that is unrelated to whole-body NO production. This trial was registered at clinicaltrials.gov as NCT01173354 and NCT01172314.
Authors: Claudia R Morris; Mirjana Poljakovic; Lisa Lavrisha; Lorenzo Machado; Frans A Kuypers; Sidney M Morris Journal: Am J Respir Crit Care Med Date: 2004-04-07 Impact factor: 21.405
Authors: M P K J Engelen; C L N De Castro; E P A Rutten; E F M Wouters; A M W J Schols; N E P Deutz Journal: Clin Nutr Date: 2012-06-06 Impact factor: 7.324
Authors: Olaf Holz; David S DeLuca; Stefan Roepcke; Thomas Illig; Klaus M Weinberger; Christian Schudt; Jens M Hohlfeld Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-01-06
Authors: Mariëlle P K J Engelen; Renate Jonker; John J Thaden; Gabriella A M Ten Have; Moon Sun Jeon; Srinivasan Dasarathy; Nicolaas E P Deutz Journal: Clin Nutr Date: 2020-01-29 Impact factor: 7.324
Authors: Mariëlle P K J Engelen; Renate Jonker; Hooriya Sulaiman; Helena L Fisk; Philip C Calder; Nicolaas E P Deutz Journal: Am J Clin Nutr Date: 2022-09-02 Impact factor: 8.472
Authors: Alaadin Vögeli; Manuel Ottiger; Marc A Meier; Christian Steuer; Luca Bernasconi; Andreas Huber; Mirjam Christ-Crain; Christoph Henzen; Claus Hoess; Robert Thomann; Werner Zimmerli; Beat Mueller; Philipp Schuetz Journal: Lung Date: 2017-08-29 Impact factor: 2.584
Authors: Nicolaas E P Deutz; John J Thaden; Gabriella A M Ten Have; Dillon K Walker; Mariëlle P K J Engelen Journal: Metabolism Date: 2017-10-03 Impact factor: 8.694
Authors: Clayton L Cruthirds; Nicolaas E P Deutz; Rajesh Harrykissoon; Anthony J Zachria; Mariëlle P K J Engelen Journal: Clin Nutr Date: 2022-03-03 Impact factor: 7.324
Authors: Yang Liu; Kun Huang; Yahui Wang; Erqiang Hu; Benliang Wei; Zhaona Song; Yuqing Zou; Luanfeng Ge; Lina Chen; Wan Li Journal: Biomed Res Int Date: 2020-12-29 Impact factor: 3.411